Diana G. Wang

1.2k total citations · 1 hit paper
8 papers, 749 citations indexed

About

Diana G. Wang is a scholar working on Molecular Biology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Diana G. Wang has authored 8 papers receiving a total of 749 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Genetics and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Diana G. Wang's work include Chronic Lymphocytic Leukemia Research (2 papers), Brain Metastases and Treatment (2 papers) and Glioma Diagnosis and Treatment (2 papers). Diana G. Wang is often cited by papers focused on Chronic Lymphocytic Leukemia Research (2 papers), Brain Metastases and Treatment (2 papers) and Glioma Diagnosis and Treatment (2 papers). Diana G. Wang collaborates with scholars based in United States and Switzerland. Diana G. Wang's co-authors include Mark R. Lundquist, Cindy Hodakoski, Lewis C. Cantley, Benjamin D. Hopkins, Yan Ma, Andrea Sboner, Chantal Pauli, Rohan Bareja, Xing Du and Himisha Beltran and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Molecular Cell.

In The Last Decade

Diana G. Wang

8 papers receiving 741 citations

Hit Papers

Suppression of insulin feedback enhances the efficacy of ... 2018 2026 2020 2023 2018 100 200 300 400

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Diana G. Wang United States 6 496 225 170 165 148 8 749
Noga Gadir United States 10 696 1.4× 186 0.8× 99 0.6× 110 0.7× 86 0.6× 18 871
Jamie C. Stanford United States 8 509 1.0× 181 0.8× 533 3.1× 93 0.6× 109 0.7× 8 1.1k
Erica H. Bell United States 15 567 1.1× 468 2.1× 172 1.0× 201 1.2× 41 0.3× 42 984
So Mee Kwon South Korea 18 510 1.0× 337 1.5× 199 1.2× 140 0.8× 75 0.5× 29 892
Louise Flanagan Ireland 10 282 0.6× 158 0.7× 319 1.9× 51 0.3× 71 0.5× 13 762
Shao-Qing Kuang United States 16 574 1.2× 142 0.6× 235 1.4× 275 1.7× 26 0.2× 17 1.1k
Ulrika Andersson Sweden 14 376 0.8× 194 0.9× 131 0.8× 99 0.6× 77 0.5× 29 692
Olivier Calvayrac France 15 430 0.9× 212 0.9× 134 0.8× 146 0.9× 37 0.3× 24 875
Norimasa Matsutani Japan 8 435 0.9× 208 0.9× 293 1.7× 82 0.5× 101 0.7× 8 797
Crystal M. Weyman United States 15 506 1.0× 175 0.8× 84 0.5× 50 0.3× 62 0.4× 26 658

Countries citing papers authored by Diana G. Wang

Since Specialization
Citations

This map shows the geographic impact of Diana G. Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diana G. Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diana G. Wang more than expected).

Fields of papers citing papers by Diana G. Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diana G. Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diana G. Wang. The network helps show where Diana G. Wang may publish in the future.

Co-authorship network of co-authors of Diana G. Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Diana G. Wang. A scholar is included among the top collaborators of Diana G. Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diana G. Wang. Diana G. Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Barrios, Dulce M., Diana G. Wang, Victoria Blinder, et al.. (2020). Prevalence and characterization of dermatologic adverse events related to alpelisib (BYL719) in breast cancer patients.. Journal of Clinical Oncology. 38(15_suppl). 1063–1063. 2 indexed citations
2.
Wang, Diana G., Dulce M. Barrios, Victoria Blinder, et al.. (2020). Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer. Breast Cancer Research and Treatment. 183(1). 227–237. 30 indexed citations
3.
Gillespie, Erin F., Diana G. Wang, N. Ari Wijetunga, et al.. (2020). Replacing 30 Gy in 10 fractions with stereotactic body radiation therapy for bone metastases: A large multi-site single institution experience 2016–2018. Clinical and Translational Radiation Oncology. 25. 75–80. 6 indexed citations
4.
Wang, Diana G., Marcia N. Paddock, Mark R. Lundquist, et al.. (2019). PIP4Ks Suppress Insulin Signaling through a Catalytic-Independent Mechanism. Cell Reports. 27(7). 1991–2001.e5. 40 indexed citations
5.
Lockney, Natalie A., Diana G. Wang, Xin Pei, et al.. (2018). Phosphatidylinositol-3-Kinase Mutations Are Associated With Increased Local Failure in Brain Metastases Treated With Radiation. International Journal of Radiation Oncology*Biology*Physics. 101(4). 833–844. 3 indexed citations
6.
Hopkins, Benjamin D., Chantal Pauli, Xing Du, et al.. (2018). Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 560(7719). 499–503. 481 indexed citations breakdown →
7.
Lockney, Natalie A., Diana G. Wang, Philip H. Gutin, et al.. (2017). Clinical outcomes of patients with limited brain metastases treated with hypofractionated (5 × 6 Gy) conformal radiotherapy. Radiotherapy and Oncology. 123(2). 203–208. 17 indexed citations
8.
Snyder, Eric L., Hideo Watanabe, Margaret Magendantz, et al.. (2013). Nkx2-1 Represses a Latent Gastric Differentiation Program in Lung Adenocarcinoma. Molecular Cell. 50(2). 185–199. 170 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026